nach oben

Breast Cancer Research and Treatment

Erschienen in:

28.04.2022 | Epidemiology

Hypertensive diseases of pregnancy and risk of breast cancer in the Black Women’s Health Study

verfasst von: Zahna Bigham, Yvonne Robles, Karen M. Freund, Julie R. Palmer, Kimberly A. Bertrand

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Compared to white women, Black women have increased risk of developing hypertensive diseases of pregnancy (HDOP) and have a higher incidence of aggressive breast cancer subtypes. Few studies of HDOP and breast cancer risk have included large numbers of Black women. This study examined the relation of HDOP to incidence of breast cancer overall and by estrogen receptor (ER) status in Black women.

Methods

We followed 42,982 parous women in the Black Women’s Health Study, a nationwide prospective study of Black women. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) to assess associations of self-reported HDOP, including preeclampsia and gestational hypertension, with breast cancer incidence overall and by ER subtype, adjusted for age and established breast cancer risk factors.

Results

Over 20 years of follow-up, we identified 2376 incident breast cancer cases. History of HDOP (11.7%) was not associated with breast cancer risk overall (HR 0.98; 95% CI 0.87, 1.11). HRs for invasive ER+ and ER– breast cancer were 1.11 (95% CI 0.93, 1.34) and 0.81 (95% CI 0.61, 1.07), respectively.

Conclusions

HDOP was not associated with risk of overall breast cancer in Black women. A suggestive inverse association with ER– breast cancer may reflect an anti-tumorigenic hormone profile in HDOP, but those results require confirmation in other studies.

Folk DM (2018) Hypertensive disorders of pregnancy: overview and current recommendations. J Midwifery & Women’s Health 63:289–300. https://doi.org/10.1111/jmwh.12725CrossRef

Umesawa M, Kobashi G (2017) Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res 40:213–220. https://doi.org/10.1038/hr.2016.126CrossRefPubMed

Butwick AJ, Druzin ML, Shaw GM, Guo N (2020) Evaluation of US state-level variation in hypertensive disorders of pregnancy. JAMA Netw Open 3:e2018741. https://doi.org/10.1001/jamanetworkopen.2020.18741CrossRefPubMedPubMedCentral

Bello NA, Zhou H, Cheetham TC et al (2021) Prevalence of hypertension among pregnant women when using the 2017 American college of cardiology/American heart association blood pressure guidelines and association with maternal and fetal outcomes. JAMA Netw Open 4:e213808. https://doi.org/10.1001/jamanetworkopen.2021.3808CrossRefPubMedPubMedCentral

Fingar K, Mabry-Hernandez I, Ngo-Metzger Q, et al (2017) Delivery Hospitalizations Involving Preeclampsia and Eclampsia, 2005–2014. HCUP Statistical Brief. Agency for Healthcare Research and Quality, Rockville, MD

DeSantis CE, Fedewa SA, Goding Sauer A et al (2016) Breast cancer statistics, 2015 Convergence of incidence rates between black and white women: Breast Cancer Statistics 2015. CA A Cancer J Clinicians 66:31–42. https://doi.org/10.3322/caac.21320CrossRef

DeSantis CE, Ma J, Gaudet MM et al (2019) Breast cancer statistics 2019. CA A Cancer J Clinicians 69:438–451. https://doi.org/10.3322/caac.21583@10.1002/(ISSN)1097-0142.breastcancercollectionCrossRef

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018: Cancer Statistics. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442CrossRefPubMed

DeSantis CE, Jemal A (2019) Re: black–white breast cancer incidence trends: effects of ethnicity. J Nat Cancer Instit 111:99–100. https://doi.org/10.1093/jnci/djy162CrossRef

10.

Bejaimal SAD, Wu CF, Lowe J et al (2016) Short-term risk of cancer among women with previous gestational diabetes: a population-based study. Diabet Med 33:39–46. https://doi.org/10.1111/dme.12796CrossRefPubMed

11.

Brasky TM, Li Y, Jaworowicz DJ et al (2013) Pregnancy-related characteristics and breast cancer risk. Cancer Causes Control 24:1675–1685. https://doi.org/10.1007/s10552-013-0242-9CrossRefPubMedPubMedCentral

12.

Innes KE, Byers TE (2004) First pregnancy characteristics and subsequent breast cancer risk among young women. Int J Cancer 112:306–311. https://doi.org/10.1002/ijc.20402CrossRefPubMed

13.

Kim JS, Kang EJ, Woo OH et al (2013) The relationship between preeclampsia, pregnancy-induced hypertension and maternal risk of breast cancer: a meta-analysis. Acta Oncol 52:1643–1648. https://doi.org/10.3109/0284186X.2012.750033CrossRefPubMed

14.

Behrens I, Basit S, Jensen A et al (2016) Hypertensive disorders of pregnancy and subsequent risk of solid cancer-A nationwide cohort study: Hypertensive disorders of pregnancy and solid cancer. Int J Cancer 139:58–64. https://doi.org/10.1002/ijc.30065CrossRefPubMed

15.

Cnattingius S (2005) Pregnancy characteristics and maternal risk of breast cancer. JAMA 294:2474. https://doi.org/10.1001/jama.294.19.2474CrossRefPubMed

16.

Troisi R, Doody DR, Mueller BA (2013) A linked-registry study of gestational factors and subsequent breast cancer risk in the mother. Cancer Epidemiol Biomarkers Prev 22:835–847. https://doi.org/10.1158/1055-9965.EPI-12-1375CrossRefPubMedPubMedCentral

17.

Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10:722–732CrossRef

18.

Wright LB, Schoemaker MJ, Jones ME et al (2018) Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. Int J Cancer 143:782–792. https://doi.org/10.1002/ijc.31364CrossRefPubMedPubMedCentral

19.

Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R (2002) Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer 87:971–973. https://doi.org/10.1038/sj.bjc.6600581CrossRefPubMedPubMedCentral

20.

Yang H, He W, Eriksson M et al (2018) Inherited factors contribute to an inverse association between preeclampsia and breast cancer. Breast Cancer Res 20:6. https://doi.org/10.1186/s13058-017-0930-6CrossRefPubMedPubMedCentral

21.

Pacheco NLP, Andersen A-MN, Kamper-Jørgensen M (2015) Preeclampsia and breast cancer: The influence of birth characteristics. The Breast 24:613–617. https://doi.org/10.1016/j.breast.2015.06.006CrossRefPubMed

22.

Opdahl S, Romundstad PR, Alsaker MDK, Vatten LJ (2012) Hypertensive diseases in pregnancy and breast cancer risk. Br J Cancer 107:176–182. https://doi.org/10.1038/bjc.2012.195CrossRefPubMedPubMedCentral

23.

Hajiebrahimi M, Cnattingius S, Lambe M, Bahmanyar S (2016) Pregnancy history and risk of premenopausal breast cancer-a nested case-control study. Int J Epidemiol 45:816–824. https://doi.org/10.1093/ije/dyv293CrossRefPubMed

24.

Serrand C, Mura T, Fabbro-Peray P et al (2021) Assessment of all-cause cancer incidence among individuals with preeclampsia or eclampsia during first pregnancy. JAMA Netw Open 4:e2114486. https://doi.org/10.1001/jamanetworkopen.2021.14486CrossRefPubMedPubMedCentral

25.

Troisi R, Bjørge T, Gissler M et al (2018) The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Intern Med 283:430–445. https://doi.org/10.1111/joim.12747CrossRefPubMedPubMedCentral

26.

Troisi R, Gulbech Ording A, Grotmol T et al (2018) Pregnancy complications and subsequent breast cancer risk in the mother: a Nordic population-based case-control study. Int J Cancer 143:1904–1913. https://doi.org/10.1002/ijc.31600CrossRefPubMedPubMedCentral

27.

Ma H, Henderson KD, Sullivan-Halley J et al (2010) Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. Breast Cancer Res 12:R35. https://doi.org/10.1186/bcr2589CrossRefPubMedPubMedCentral

28.

Calderon-Margalit R, Friedlander Y, Yanetz R et al (2009) Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study. Am J Obstet Gynecol 200:63.e1–5. https://doi.org/10.1016/j.ajog.2008.06.057CrossRef

29.

Kang EJ, Seo JH, Kim LY et al (2016) Pregnancy-associated risk factors of postpartum breast cancer in korea: a nationwide health insurance database study. PLoS ONE 11:e0168469. https://doi.org/10.1371/journal.pone.0168469CrossRefPubMedPubMedCentral

30.

Sun M, Fan Y, Hou Y, Fan Y (2018) Preeclampsia and maternal risk of breast cancer: a meta-analysis of cohort studies. J Matern Fetal Neonatal Med 31:2484–2491. https://doi.org/10.1080/14767058.2017.1342806CrossRefPubMed

31.

Paltiel O, Friedlander Y, Tiram E et al (2004) Cancer after pre-eclampsia: follow up of the Jerusalem perinatal study cohort. BMJ 328:919. https://doi.org/10.1136/bmj.38032.820451.7CCrossRefPubMedPubMedCentral

32.

Lin L-T, Hu L-Y, Tang P-L et al (2017) Do racial differences exist in the association between pregnancy-induced hypertension and breast cancer risk? Hypertens Pregnancy 36:138–144. https://doi.org/10.1080/10641955.2016.1258411CrossRefPubMed

33.

Walfisch A, Kessous R, Davidson E et al (2015) Pre-eclampsia and Future Female Malignancy. Hypertens Pregnancy 34:456–463. https://doi.org/10.3109/10641955.2015.1071838CrossRefPubMed

34.

Rosenberg L, Adams-Campbell L (1972) The Black Women’s health study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc 50:56–58

35.

Gillon TER, Pels A, von Dadelszen P et al (2014) Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS ONE 9:e113715. https://doi.org/10.1371/journal.pone.0113715CrossRefPubMedPubMedCentral

36.

Bellamy L, Casas J-P, Hingorani AD, Williams DJ (2007) Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335:974. https://doi.org/10.1136/bmj.39335.385301.BECrossRefPubMedPubMedCentral

37.

Kamper-Jørgensen M, Gammill HS, Nelson JL (2018) Preeclampsia and scleroderma: a prospective nation-wide analysis. Acta Obstet Gynecol Scand 97:587–590. https://doi.org/10.1111/aogs.13296CrossRefPubMedPubMedCentral

38.

Weissgerber TL, Mudd LM (2015) Preeclampsia and Diabetes. Curr Diab Rep 15:579. https://doi.org/10.1007/s11892-015-0579-4CrossRefPubMedCentral

39.

S Ananth Karumanchi, Kee-Hak Kim, Phyllis August Preeclampsia: Pathogenesis. In: UpToDate. https://www.uptodate.com/contents/preeclampsia-pathogenesis. Accessed 22 Jul 2020

40.

Shu C, Han S, Xu P et al (2021) Estrogen and preeclampsia: potential of estrogens as therapeutic agents in preeclampsia. DDDT 15:2543–2550. https://doi.org/10.2147/DDDT.S304316CrossRefPubMedPubMedCentral

41.

Lan K-C, Lai Y-J, Cheng H-H et al (2020) Levels of sex steroid hormones and their receptors in women with preeclampsia. Reprod Biol Endocrinol 18:12. https://doi.org/10.1186/s12958-020-0569-5CrossRefPubMedPubMedCentral

42.

Jobe SO, Tyler CT, Magness RR (2013) Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction. Hypertension 61:480–487. https://doi.org/10.1161/HYPERTENSIONAHA.111.201624CrossRefPubMed

43.

Hertig A, Liere P, Chabbert-Buffet N et al (2010) Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol 203:477.e1-477.e9. https://doi.org/10.1016/j.ajog.2010.06.011CrossRef

44.

Wan J, Hu Z, Zeng K et al (2018) The reduction in circulating levels of estrogen and progesterone in women with preeclampsia. Pregnancy Hypertension 11:18–25. https://doi.org/10.1016/j.preghy.2017.12.003CrossRefPubMed

45.

Berkane N, Liere P, Oudinet J-P et al (2017) From Pregnancy to Preeclampsia: A Key Role for Estrogens. Endocr Rev 38:123–144. https://doi.org/10.1210/er.2016-1065CrossRefPubMed

46.

Hübinette A, Lichtenstein P, Brismar K et al (2003) Serum insulin-like growth factors in normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 82:1004–1009PubMed

47.

Bando H, Weich HA, Brokelmann M et al (2005) Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 92:553–561. https://doi.org/10.1038/sj.bjc.6602374CrossRefPubMedPubMedCentral

48.

Furuya M, Kurasawa K, Nagahama K et al (2011) Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia. J Pregnancy 2011:1–10. https://doi.org/10.1155/2011/123717CrossRef

49.

Harmon AC, Cornelius DC, Amaral LM et al (2016) The role of inflammation in the pathology of preeclampsia. Clin Sci 130:409–419. https://doi.org/10.1042/CS20150702CrossRef

50.

Chappell LC, Seed PT, Briley AL et al (1999) Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. The Lancet 354:810–816. https://doi.org/10.1016/S0140-6736(99)80010-5CrossRef

51.

Roberts J, Cooper D (2001) Pathogenesis and genetics of pre-eclampsia. The Lancet 357:53–56. https://doi.org/10.1016/S0140-6736(00)03577-7CrossRef

52.

Hubel CA, Roberts JM, Taylor RN et al (1989) Lipid peroxidation in pregnancy: New perspectives on preeclampsia. Am J Obstet Gynecol 161:1025–1034. https://doi.org/10.1016/0002-9378(89)90778-3CrossRefPubMed

53.

Lee JD, Cai Q, Shu XO, Nechuta SJ (2017) The role of biomarkers of oxidative stress in breast cancer risk and prognosis: a systematic review of the epidemiologic literature. Journal of Women’s Health 26:467–482. https://doi.org/10.1089/jwh.2016.5973CrossRefPubMedPubMedCentral

54.

Redman CW (2005) Latest advances in understanding preeclampsia. Science 308:1592–1594. https://doi.org/10.1126/science.1111726CrossRefPubMed

55.

Boij R, Svensson J, Nilsson-Ekdahl K et al (2012) Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 68:258–270. https://doi.org/10.1111/j.1600-0897.2012.01158.xCrossRefPubMed

56.

Troisi R, Weiss HA, Hoover RN et al (1998) Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9:641–647CrossRef

57.

Troisi R, Innes KE, Roberts JM, Hoover RN (2007) Preeclampsia and maternal breast cancer risk by offspring gender: do elevated androgen concentrations play a role? Br J Cancer 97:688–690. https://doi.org/10.1038/sj.bjc.6603921CrossRefPubMedPubMedCentral

58.

Terry MB, Perrin M, Salafia CM et al (2007) Preeclampsia, pregnancy-related hypertension, and breast cancer risk. Am J Epidemiol 165:1007–1014. https://doi.org/10.1093/aje/kwk105CrossRefPubMed

59.

Diehl CL, Brost BC, Hogan MC et al (2008) Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire. Am J Obstet Gynecol 198:e11–e13. https://doi.org/10.1016/j.ajog.2007.09.038CrossRefPubMed

60.

Dietz P, Bombard J, Mulready-Ward C et al (2014) Validation of self-reported maternal and infant health indicators in the pregnancy risk assessment monitoring system. Matern Child Health J 18:2489–2498. https://doi.org/10.1007/s10995-014-1487-yCrossRefPubMedPubMedCentral

61.

Coolman M, de Groot CJM, Jaddoe VW et al (2010) Medical record validation of maternally reported history of preeclampsia. J Clin Epidemiol 63:932–937. https://doi.org/10.1016/j.jclinepi.2009.10.010CrossRefPubMed

62.

Carter EB, Stuart JJ, Farland LV et al (2015) Pregnancy complications as markers for subsequent maternal cardiovascular disease: validation of a maternal recall questionnaire. Journal of Women’s Health 24:702–712. https://doi.org/10.1089/jwh.2014.4953CrossRefPubMedPubMedCentral

63.

Barton JR, O’Brien JM, Bergauer NK et al (2001) Mild gestational hypertension remote from term: Progression and outcome. Am J Obstet Gynecol 184:979–983. https://doi.org/10.1067/mob.2001.112905CrossRefPubMed

64.

Magee LA, von Dadelszen P, Singer J et al (2016) The CHIPS randomized controlled trial (Control of Hypertension in Pregnancy Study): is severe hypertension just an elevated blood Pressure? Hypertension 68:1153–1159. https://doi.org/10.1161/HYPERTENSIONAHA.116.07862CrossRefPubMed

65.

Brown MA, Magee LA, Kenny LC et al (2018) Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 72:24–43. https://doi.org/10.1161/HYPERTENSIONAHA.117.10803CrossRefPubMed

Titel: Hypertensive diseases of pregnancy and risk of breast cancer in the Black Women’s Health Study
verfasst von: Zahna Bigham
Yvonne Robles
Karen M. Freund
Julie R. Palmer
Kimberly A. Bertrand
Publikationsdatum: 28.04.2022
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-022-06606-3

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Bildnachweise

Frau nutzt Gehhilfe /© Photographee.eu / Fotolia (Symbolbild mit Fotomodellen), Darstellung der Dosisverteilung bei Bestrahlung eines Prostatakarzinoms/© Degener, S et al. / all rights reserved Springer Medizin Verlag GmbH, Frau mit Tablette und Wasserglas in Händen/© fizkes / stock.adobe.com (Symbolbild mit Fotomodell), Ärztin und künstliche Intelligenz sehen sich Befunde an/© Alexander Limbach / Zoonar/picture alliance (Symbolbild mit Fotomodell)

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Hypertensive diseases of pregnancy and risk of breast cancer in the Black Women’s Health Study

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers

Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ

Hypoxia and anaerobic metabolism relate with immunologically cold breast cancer and poor prognosis

Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy

Risk factors for psychological morbidity and the protective role of coping self-efficacy in young women with breast cancer early in diagnosis: a national multicentre cohort study

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Update Onkologie